¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"È¿"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
curdling ferment
ÀÀÀ¯¹ßÈ¿¼Ò
cytolytic ferment
¼¼Æ÷¿ëÇØ¹ßÈ¿¼Ò
cytopathic effect
¼¼Æ÷º´º¯È¿°ú
cytosolic enzyme
¼¼Æ÷¾×È¿¼Ò
carrier effect
¿î¹Ýüȿ°ú
carry-over effect
ÀÜÈ¿
catalase
°ú»êȼö¼ÒºÐÇØÈ¿¼Ò, īŻ¶ó¾ÆÁ¦
cavitation effect
°øµ¿È¿°ú
ceiling effect
ÃÖ°íÈ¿°ú
chitinase
ŰƾºÐÇØÈ¿¼Ò
cholesterol esterase
ÄÝ·¹½ºÅ×·Ñ¿¡½ºÅ׸£ºÐÇØÈ¿¼Ò
choline acetyltransferase
Äݸ°¾Æ¼¼Æ¿Àüȯȿ¼Ò
dehydrase
Å»¼ö¼ÒÈ¿¼Ò
dehydratase
Å»¼öÈ¿¼Ò
dehydrogenase
Å»¼ö¼ÒÈ¿¼Ò
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
6
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
reverse transcriptase
¿ªÀü»çÈ¿¼Ò, ¿ªÀü»ç
uricase
¿ä»êºÐÇØÈ¿¼Ò
urease
¿ä¼ÒºÐÇØÈ¿¼Ò
validity
Ÿ´ç¼º, È¿·Â, Ÿ´çµµ
effective blood volume
À¯È¿Ç÷¾×·®
zymosis
¹ßÈ¿
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
cumulative effect
´©ÀûÈ¿°ú, ÃàÀûÈ¿°ú
curative effect
Ä¡·áÈ¿°ú
curdling enzyme
ÀÀÀ¯È¿¼Ò
curdling ferment
ÀÀÀ¯¹ßÈ¿¼Ò
cytochrome oxidase test
½ÃÅäÅ©·Ò»êÈÈ¿¼Ò°Ë»ç
cytolytic ferment
¼¼Æ÷¿ëÇØ¹ßÈ¿¼Ò
cytopathic effect
¼¼Æ÷º´º¯È¿°ú
cytosolic enzyme
¼¼Æ÷ÁúÈ¿¼Ò
effective capacity
À¯È¿¿ë·®
effective charge
À¯È¿ÀüÇÏ
effective chlorine
À¯È¿¿°¼Ò
effective current
À¯È¿Àü·ù
efficient coitus
À¯È¿¼º±³
isoeffect curve
µîÈ¿°ú°î¼±
minimal effective analgesic concentration
ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
Lactobacillus fermenti
¹ßÈ¿¶ôÆ®»ê°£±Õ.
Lactobacillus fermenti
¹ßÈ¿¶ôÆ®»ê°£±Õ.
Lipase
Áö¹æºÐÇØÈ¿¼Ò(ò·Û¸ÝÂú°ý£áÈ), ¶óÀÌÆäÀÌÁî
Lipoprotein lipase
Áö´Ü¹é(ò·Ó±ÛÜ) Áö¹æºÐÇØÈ¿¼Ò(ò·Û¸ÝÂú°ý£áÈ)
MAO inhibitor
¸ð³ë¾Æ¹Î»êÈÈ¿¼Ò ¾ïÁ¦Á¦.
MAO inhibitor
¸ð³ë¾Æ¹Î »êÈÈ¿¼Ò ÀúÇØÁ¦.
MAO inhibitor(MAOI)
´Ü°¡¾Æ¹Î»êÈÈ¿¼Ò¾ïÁ¦Á¦
MAO=> monoamine oxldase
¸ð³ë¾Æ¹Î»êÈÈ¿¼Ò.
MAO=£¾monoamine oxidase
¸ð³ë¾Æ¹Î»ê ÈÈ¿¼Ò.
MAO=£¾monoamine oxldase
¸ð³ë¾Æ¹Î»ê ÈÈ¿¼Ò.
MED=> minimum effective dose
ÃÖ¼ÒÀ¯È¿·®.
MED=£¾minimum effective dose
ÃÖ¼ÒÀ¯È¿·®.
NADH dehydrogenase
NADH Å»¼ö¼ÒÈ¿¼Ò
NADH-methemoglobin reductase
NADH-¸ÞÆ®Çì¸ð±Û·Îºó ȯ¿øÈ¿¼Ò
NADPH-dependent oxidase system
NADPH-ÀÇÁ¸¼º »êÈÈ¿¼Ò°è
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
enzyme inhibition
È¿¼Ò¾ïÁ¦.
enzyme-linked immunoelectrotransfer blot
È¿¼Ò¿¬°ü ¸é¿ªÀü±âÀü´ÞÁ¡
enzyme-linked immunosorbent assay
È¿¼Ò¿¬°ü¸é¿ªÈíÂø¹ý
ferment fever
È¿¼Ò¿(ý£áÈæð).
enzymotherapy
È¿¼Ò¿ä¹ý.
zymogen
È¿¼Ò¿ø(ý£áÈê«)
zymogen
È¿¼Ò¿ø(ý£áÈê«)
zymogen
È¿¼Ò¿ø(ý£áÈê«), ÀÚÀ̸ðƾ.
zymogen granule
È¿¼Ò¿ø°ú¸³
zymogen granule
È¿¼Ò¿ø°ú¸³(ý£áÈê« ÍýØ£)
zymogen droplet
È¿¼Ò¿ø°ú¸³, È¿¿ø°ú¸³(ý£ê«Î¨í£)
zymogen droplet
È¿¼Ò¿ø°ú¸³, È¿¿ø°ú¸³(ý£ê«Î¨í£).
zymogen granule
È¿¼Ò¿ø°ú¸³, È¿¿ø°ú¸³(ý£ê«Î¨í£).
zymogenic cell
È¿¼Ò¿ø¼¼Æ÷(ý£áÈê«á¬øà).
enzyme induction
È¿¼ÒÀ¯µµ(ý£áÈë¯Óô).
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
benzidine oxidase
º¥Áöµò»êÈÈ¿¼Ò
beta (¥â)-lactamase
º£Å¸¶ôŸ¸¶Á¦, º£Å¸¶ôŽ °¡¼öºÐÇØÈ¿¼Ò
beta-ARK : beta-adrenergic receptor kinase
º£Å¸-¾Æµå·¹³¯¸°(¼º)¼ö¿ëü ÀλêÈÈ¿¼Ò.
beta-lactamase inhibitors
º£Å¸-¶ôޯı«È¿¼Ò¾ïÁ¦Á¦.
binaural hearing (effect)
¾çÀÌû(È¿°ú)
binaural hearing (effect)
¾çÀÌû(È¿°ú).
bioavailability
»ýü(³»)ÀÌ¿ë(È¿)À²(ßæô÷(Ò®)ì¦éÄ(üù)ëÒ), »ýü³»À¯¿ëµµ.
bioavailability
»ýü(³»)ÀÌ¿ë(È¿)À²(ßæô÷Ò®ì¦éÄüùëÒ), »ýü³»À¯¿ë¼Ò.
bioeffect
»ý¹°ÇÐÀû È¿°ú
bioeffects
»ý¹°ÇÐÀû È¿°ú (ßæÚªùÊîÜ üùÍý)
biologic effect
»ý¹°ÇÐÀû È¿°ú
biologic effects
»ý¹°ÇÐÀû È¿°ú (ßæÚªùÊîÜ üùÍý)
biological effect
»ý¹°ÇÐÀû È¿°ú
biological effectiveness
[°áÇÙ,ÀÓº´,¹ÙÀÌ] »ý¹°ÇÐÀû È¿°ú (¡üùÍý).
biological effectiveness
¾à ¸® ¹Ì»ý,±â»ý,³»°ú,°áÇÙ,ÀÓº´ ºñÀÌ »ý¹°ÇÐÀû È¿°ú (¡üùÍý).
ÀÌÀü
´ÙÀ½
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
dispensable enzyme
ºñÇʼö È¿¼Ò(Þªù±âÎý£áÈ) (ÔÒ) nonessential enzyme
dispersion effect
"ºÐ»ê È¿°ú(ÝÂߤüùÍý), (ÔÒ) dispersion forces"
DNA-relaxing enzyme
DNAÀÌ¿Ï È¿¼Ò(ì¬èÐý£áÈ) (ÔÒ) topoisomerase
DNA restriction enzyme
DNA Á¦ÇÑ È¿¼Ò(ð¤ùÚý£áÈ) (ÔÒ) restriction enzyme
Dorn effect
"µ· È¿°ú(üùÍý), (ÔÒ) sedimentation potential"
drag effect
²ø¸² È¿°ú(üùÍý) (ÔÒ) solvent drag
drug-detoxication enzyme
¾à¹°Çص¶ È¿¼Ò(å·Úªú°Ô¸ý£áÈ) (ÔÒ) drug-metabolizing enzyme
drug-metbolizing enzyme
¾à¹°´ë»ç È¿¼Ò(å·ÚªÓÛÞóý£áÈ)
dual-effect mutant
ÀÌÁßÈ¿°ú º¯ÀÌü(ì£ñìüùÍýܨì¶ô÷)
early enzyme
Á¶±â È¿¼Ò(ðÄÑ¢ý£áÈ)
ectoenzyme
¿¢ÅäÈ¿¼Ò(ý£áÈ)
effective concentration
À¯È¿ ³óµµ (êóüùÒØÓø)
effective half-life
À¯È¿ ¹Ý°¨±â(êóüùÚâÊõÑ¢)
effective lethal phase
À¯È¿ Ä¡»ç±â(êóüùöÈÞÝÑ¢)
effector
"ÀÛµ¿ÀÚ(íÂÔÑí), È¿°úÀÚ(üùÍýí)"
ÀÌÀü
´ÙÀ½
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
5
ÆäÀÌÁö:
6
ÄÚµå
¿µ¹®
ÇѱÛ
T50.1
Loop [high-ceiling] diuretics
°í¸®[°íÈ¿´É]ÀÌ´¢Á¦
T50.2
Carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics
ź»êÅ»¼öÈ¿¼Ò ¾ïÁ¦Á¦, º¥Á¶Å¸À̾ƴÙÀ̾ÆÀÚÀÌµå ¹× ±âŸ ÀÌ´¢Á¦
T52
Toxic effect of organic solvents
À¯±â¿ëÁ¦ÀÇ Áßµ¶È¿°ú
Y43.6
Enzymes, NEC
´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº È¿¼Ò·ù
Y52.4
Angiotensin-converting-enzyme inhibitors
¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¾à¹°
ÀÌÀü
´ÙÀ½
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
¼³¸í
effective blood volume
À¯È¿ Ç÷¾×·®
effective diameter
À¯È¿ Áö¸§
effective dose 50%
Áß°£ À¯È¿·®, 50% À¯È¿·®
µ¿¹°¿¡ µ¶¼Ò³ª ¾à¹° Åõ¿© ½Ã, 50%ÀÇ µ¿¹°¿¡¼ À¯È¿ÇÏ´Ù°í ÃßÁ¤µÇ´Â ¿ë·®.
effective focal spot
½ÇÈ¿ ÃÊÁ¡
effective mass
À¯È¿ Áú·®
effective osmolality
À¯È¿ »ïÅõÁú ³óµµ
effective ratio
À¯È¿À²
¾î´À ÇѰè±îÁö´Â ¾àÁ¦ ¿ë·®°ú À¯È¿À²Àº ºñ·ÊÇÑ´Ù. ÇѰè À̻󿡼´Â ºÎÀÛ¿ëÀÌ ³ªÅ¸³´Ù.
effective tonicity
À¯È¿ Àå·Â
effective weight
À¯È¿ Áß·®
effector
È¿°ú±â, È¿°úü, ÁÖÈ¿ ÀÎÀÚ, ÀÛµ¿ ¹°Áú, ÁÖÈ¿ ±â°ü
½Å°æ Ãæµ¿À» Á÷Á¢ ¼ö¿ëÇÏ¿© ¹ÝÀÀÇÏ´Â ±ÙÀ̳ª ¼±ÀÇ ÀÏÁ¤ ºÎºÐ.
effector-inhibitory factor
È¿°ú±â ¾ïÁ¦ ÀÎÀÚ
efferent effect
¿ø½É È¿°ú
efficacy
È¿´É
°á°ú¸¦ À¯µµÇÏ´Â ¾àÁ¦³ª Ä¡·áÀÇ ´É·Â.
efficiency of ablation per pulse
ÆÞ½º´ç Á¦°Å È¿À²
efficient
È¿°úÀûÀÎ, È¿À²ÀûÀÎ
ÀÌÀü
´ÙÀ½
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
allostery
¾Ë·Î½ºÅ׸¯ È¿°ú 6
altogether
¾ÆÁÖÀüÇô;ÀüºÎÇØ¼;´ëü·Î-ÀüüÀû È¿°ú )
annul
¹«È¿·ÎÇÏ´Ù;Ãë¼ÒÇÏ´Ù
annulment
Ãë¼Ò;½ÇÈ¿;ÆóÁö;(È¥ÀÎÀÇ)¹«È¿ ¼±¾ð
antidotal
ÇØµ¶Á¦ÀÇ;ÇØµ¶ÀÇ(È¿ÇèÀÌ ÀÖ´Â)
antiinflammatoru
¿°Áõ¿¡ È¿ÇèÀÌ ÀÖ´Â;Ç׿°ÁõÀÇ;Ç׿°Áõ¾à
antipsychotic
Á¤½Åº´¿¡ È¿Çè ÀÖ´Â;Á¤½Åº´ Ä¡·á¾à;Ç×Á¤½Åº´¾à
apoenzyme
¾ÖÆ÷ È¿¼Ò
aposematic
(ü»ö µîÀÌ ¹æ¾î È¿°ú°¡ ÀÖ´Â)°æ°è(»ö)ÀÇ
arginase
¾Æ¸£±â³ª¾ÆÁ¦(¾Æ¸£±â´ÑÀ» ¿ä¼Ò·Î ºÐÇØÇÏ´Â È¿¼Ò)
avail
µµ¿òÀ̵ǴÙ;¼Ò¿ëÀ̵ǴÙ;ÀÌ·Ó´Ù;ÀÌÀÍ;È¿¿ë
availability
À¯È¿;À¯ÀÍ;µµ¿ò;¾µ¸ð
available
ÀÌ¿ëÇÒ ¼ö ÀÖ´Â;¼Õ¿¡³ÖÀ»¼öÀÖ´Â;Àü½ÉÇÒ¼öÀÖ´Â;¿©°¡°¡ÀÖ´Â;À¯È¿ÇÑ
avoidance
µµÇÇ;ȸÇÇ;¹«È¿
background
¹è°æ;¹ÙÅÁ»ö;¼Ò¾ç;À½¾ÇÈ¿°ú
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
ÀÌÀü
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÇÑÀÚ
ÀÌÀü
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÇÑÀÚ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
ÀÌÀü
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
ÄÚµå
¿µ¹®
ÇѱÛ
ÀÌÀü
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
¼³¸í
ÀÌÀü
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú:
0
ÆäÀÌÁö:
6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú:
0
ÆäÀÌÁö:
6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
6
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½